From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis

摘要: Background Immunosuppressive drugs have been used in the treatment of multiple sclerosis (MS) for a long time. Today, orally available second generation immunosuppressive agents approved or are filed licensing as MS therapeutics. Due to semi-selective targeting cellular processes, these second-generation compounds might rather be immunomodulatory. For example, Teriflunomide inhibits de novo pyrimidine synthesis and thus only targets rapidly proliferating cells, including lymphocytes. It is first line disease modifying therapy (DMT) relapsing-remitting (RRMS). Methods Review online content related oral immunosuppressants with an emphasis on Teriflunomide. Results Cladribine that efficient patients. Teriflunomide, daily dose 14 mg reduces annualized relapse rate (ARR) by more than 30% disability progression compared placebo. ARR about 50% placebo but has not yet licensed due unresolved safety concerns. We also discuss significance older Azathioprine, Mycophenolate mofetile, Cyclophosphamide current therapy. Conclusion shown favorable efficacy profile RRMS therapeutic option distinct group adult patients RRMS.